Here's Why Americans See Prescription Drug Advertisements All Day Long

Here's Why Americans See Prescription Drug Advertisements All Day Long

June 17, 2022

Television advertisements for prescription drugs are illegal in virtually every country on the planet — but not in the U.S., where 80 such ads air, on average, every hour on Americans' televisions.

Story at a glance:

* Research from healthcare advertising technology company DeepIntent revealed that 27% of people spoke to their doctor about a medical treatment after they learned about it from an ad.

* Earlier data found that "pharmaceutical ads can empower patients to take a more active role in researching treatments" and "advertising influences patients' decision to follow through in taking drugs prescribed by their doctors."

* The most common action that people take after viewing a drug ad is to conduct research, and this research becomes the most important factor in medication adherence — even more than the person's own previous experience taking the drug.

* Marketers intend to use increasingly targeted ads via your smart TV, cellphone and desktop computer to increase drug sales even more.

* DeepIntent CEO Chris Paquette said in a news release, "We have evidence that more relevant advertising drives real results for our clients."

Television advertisements for prescription drugs are illegal in virtually every country on the planet — but not in the U.S., where 80 such ads air, on average, every hour on Americans' televisions.

"Ask your doctor," the narrators tell viewers, urging them to bring up the latest name-brand drugs at their next physician's visit.

Before the 1980s, these types of direct-to-consumer (DTC) ads were unheard of, even in the U.S., but within a few decades, they became among the most common public health messages seen by Americans.

This marketing shift turned out to be incredibly lucrative for Big Pharma, but its effects on public health — and individual health — are highly questionable, as the ads continue to drive consumers to request drugs from their doctors, whether they need them or not.

FDA's loose guidelines paved the way for TV drug ads

Before the 1980s, pharmaceutical companies marketed directly to doctors, instead of to patients. Drug industry executives even told Congress at the time that they believed directly advertising drugs to consumers was not "in the public health interest" and "cannot safely be accomplished."

A cultural shift soon emerged, however, to empower patients to be more involved in their own healthcare, instead of solely listening to their doctors. Advertisers jumped on the trend but, still, drug advertisements to consumers only appeared in print ads, including in magazines, but not on TV.

This was due to the U.S. FDA's requirements to include all drug risks and side effects in the ads, which could be done on pages of print but was much more difficult to accomplish on TV or radio commercials.

A strange loophole existed, however, which allowed drug ads to run without stating the risks and side effects, as long as it also didn't mention the disease the drug was intended to treat. This is highly likely related to the industry finally capturing the federal regulatory agencies responsible for protecting the public.

Not surprisingly, this led to confusion, prompting a loosened requirement from the FDA in 1997, which stated that ads only had to include the drug's "major" side effects and refer viewers to a source where they could find the rest.

Even if viewers do end up seeking out the full list of side effects, the info seldom scares patients away. Everything is designed to make you tune out the risks and view the drug in a desirable light, from actors who use an appealing voice tone to beautiful images and music choices.

The removal of the requirement to list all drug side effects in ads paved the way for on-air drug ads, and the rest is history. By 2004, annual spending on drug advertisements quadrupled, making name-brand drugs like Lipitor, Lunesta, Xanax and Ambien household names.

Patient requests have `profound' effect on doctors

By 2003, U.S. DTC advertising of prescription drugs had reached $3.2 billion. For comparison, it reached $6.58 billion in 2020, excluding social media.

The profound way it influenced patients was recognized from the start, with critics stating that the ads led to over-prescribing of "unnecessary, expensive and potentially harmful medications."

By 2005, a randomized controlled trial had been published in the Journal of the American Medical Association (JAMA) to determine the influence of patients' requests for directly advertised drugs, in this case antidepressants.

Patient actors visited physicians, describing symptoms of depression in half of the visits and in the other half stating "they were feeling down," a description of an adjustment disorder that doesn't typically require immediate drug treatment.

In some of the visits, the patients mentioned seeing a commercial for the antidepressant Paxil, while in others they didn't mention any medications.

Patients who mentioned Paxil were more likely to be referred for a mental health consultation and receive a prescription for an antidepressant, whether they were describing symptoms of depression or simply "feeling down."

According to lead study author Dr. Richard Kravitz, "For us, it typified the double-edged sword which direct-to-consumer advertising represents."

Prescribing rates for the drugs were highest when patients made general requests for medications — 76% of such visits resulted in a prescription, compared with 31% of those in which the patient made no medication request.

Targeted smart TV drug ads increase drug sales

DTC drug ads are getting "smarter" as the years go by, and now marketers are using targeted ads driven by your viewing habits, which are streamed directly to you via your smart TV.

DeepIntent, a healthcare advertising technology company "built to influence patient health and business outcomes," conducted research on consumer behaviors and ad-supported content.

The majority of "connected TV" (CTV), or smart TV, viewers (64%) said they would rather watch ads than pay more to view the content.

DeepIntent surveyed 2,900 U.S. adults on self-reported viewing habits and compared it to data gleaned using "automated content recognition (ACR) technology," which was developed in partnership with LG Ads Solutions, a provider of native ads to LG smart TVs along with "audience targeting data."

Their first finding was that while many people believe they're watching TV via cable or satellite box, most are actually streaming the content via their smart TV — "meaning that more than half of viewers may be watching CTV content without even realizing it," DeepIntent explained.

The implication is that they have a greater number of viewers than previously realized to target with their ad campaigns, via not only smart TVs but other devices like your desktop computer and smartphone.

According to DeepIntent, doing so is known to influence patient outcomes:

"DeepIntent … announced its complete integration with LG Ads Solutions' real-time ACR data repository covering more than 30 million LG smart TVs in the United States. DeepIntent is the first and only demand side platform (DSP) with this capability, offering healthcare marketers unparalleled targeting capabilities for all digital formats, including CTV, desktop and mobile.

"`For too long, healthcare marketers have struggled to reach relevant audiences at scale. By combining the targeting power of CTV with ACR data, DeepIntent's patented technology optimizes campaign audience quality and script performance in real-time,' said DeepIntent Senior Vice President of Analytics John Mangano. `Consumer research has proven that this combination influences patient outcomes.'"

27% asked their doctor about a drug from an ad

DeepIntent's research findings revealed that 30% of people said pharmaceutical ads provide helpful information to someone in their household, and 27% spoke to their doctor about a medical treatment after they learned about it from an ad.

The findings support earlier data from the company, which found that "pharmaceutical ads can empower patients to take a more active role in researching treatments" and "advertising influences patients' decision to follow through in taking drugs prescribed by their doctors."

The most common action that people take after viewing a drug ad is to conduct research, and this research becomes the most important factor in medication adherence — even more than the person's own previous experience taking the drug.

They intend to use targeted ads to increase drug sales even more. DeepIntent CEO Chris Paquette said in a news release, "We have evidence that more relevant advertising drives real results for our clients."

Through their partnership with LG Ads Solutions, DeepIntent is using native ads to drive more sales. Another tactic is native content, also known as sponsored content or branded content, which is written by marketers but passes as real journalism.

The sponsored content is a media response to banner ads that are widely ignored, ad-blocking technology and readers' almost universal dislike of pop-ups and screen takeovers.

It also fills webpages without the need to pay writers — instead, sponsors pay the media on whose site or in whose publication the content appears.

Some of the content is innocuous and even amusing, but other native content like "Could Statins Cut Alzheimer's Risk?" found on WebMD or "How Testosterone Benefits Your Body" is unabashed Pharma marketing masquerading as unbiased information.

Limitless lobbying, advertising budgets

The marketing of prescription drugs, health services, laboratory tests and even disease awareness is big business in the U.S., and spending has been on a steady uphill climb since 1997. That year, spending on medical marketing was $17.7 billion, which rose to $29.9 billion in 2016.

DTC spending increased the most rapidly, from 11.9% of total spending to 32%. DTC prescription drug ads accounted for $6 billion in spending alone in 2016, which amounted to 4.6 million ads, including 663,000 television commercials, mostly for high-cost biologics and cancer immunotherapies.

Disease awareness campaigns are another type of marketing campaign run by pharmaceutical companies geared at diseases treated by their drugs. Such campaigns rose in numbers from 44 in 1997 to 401 in 2016, with spending increasing from $177 million to $430 million over the same period.

DTC marketing for health services also rose from $542 million to $2.9 billion, with spending increases particularly notable for hospitals, dental centers, cancer centers, mental health and addiction clinics and medical services, such as home health care.

Aside from DTC advertising, Big Pharma is still marketing directly to health professionals — an area that accounted for the most professional spending, according to a JAMA study on medical marketing in the U.S.

"Pharmaceutical marketing to health professionals accounted for most spending and remains high even with new policies to limit industry influence," the researchers, from The Dartmouth Institute's Center for Medicine in the Media, noted.

"Despite the increase in marketing over 20 years, regulatory oversight remains limited."

Annual lobbying on pharmaceuticals and health products has been on the rise since 2013, and in 2021 the pharmaceutical industry was the top lobbying group in Washington, spending far more than any other industry — $356.6 million.

Among their top priorities in 2019 was fiercely opposing a bill that would reduce drug costs, and, another eye-opening statistic — nearly 60% of Big Pharma's lobbyists are former government employees.

So, when you see an advertisement for a drug on TV or your computer, resist the urge to believe that it's there to help you and see it for what it really is — a marketing tactic with the sole purpose of increasing sales for the drug industry.

https://childrenshealthdefense.org/defender/pharmaceutical-ads-prescription-drug-advertising/

Original: https://youtu.be/_5jnn1AIt7Q